US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Super League Gaming Inc.

4.17

+0.01000.24%

Volume:33.58K

Turnover:138.70K

Market Cap:3.69M

PE:-0.06

High:4.26

Open:4.22

Low:4.07

Close:4.16

Loading ...

Overview Company News Filings

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Super League Enterprise Full Year 2024 Earnings: Misses Expectations

Simply Wall St.

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Super League Enterprise Inc (SLE) Q4 2024 Earnings Call Highlights: Strategic Shifts and Growth ...

Super League Enterprise Inc reports results for the quarter ended December 31 - Earnings Summary

Super League Enterprise (SLE) Reports Q4 Loss, Misses Revenue Estimates

BRIEF-Super League Enterprise President Matt Edelman Promoted To Role Of Chief Executive Officer

Super League Enterprise Q4 2024 Adj EPS $(0.29) Misses $(0.26) Estimate, Sales $3.43M Miss $5.50M Estimate

Press Release: Super League Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Update on Strategic Discussions to Accelerate Path to Profitability and Diversify Revenues

Dow Dips 150 Points Following Trump's Auto Tariffs, Verint Systems Slides On Q4 Miss: Greed Index Remains In 'Fear' Zone

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Press Release: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Press Release: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts

Super League Enterprise Inc expected to post a loss of 26 cents a share - Earnings Preview

Press Release: Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SLE/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":4.17,"timestamp":1754424000000,"preClose":4.16,"halted":0,"volume":33579,"delay":0,"floatShares":811000,"shares":884699,"eps":-67.3644,"marketStatus":"Pre-Mkt","change":0.01,"latestTime":"08-06 05:50:21 EDT","open":4.22,"high":4.26,"low":4.07,"amount":138703.8182985,"amplitude":0.045673,"askPrice":4.16,"askSize":65,"bidPrice":4.13,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-67.3644,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1754487000000},"marketStatusCode":1,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":4.17,"postHourTrading":{"tag":"盘后","latestPrice":4.0999,"preClose":4.17,"latestTime":"19:47 EDT","volume":2175,"amount":8916.208,"timestamp":1754437626088},"volumeRatio":0.448060122599125},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":811000,"roa":"-71.33%","roe":"-1235.06%","lyrEps":-94.05048,"volumeRatio":0.448060122599125,"shares":884699,"dividePrice":0,"high":4.26,"amplitude":0.045673,"preClose":4.16,"low":4.07,"week52Low":3.91,"pbRate":"-1.07","psRate":"0.25","week52High":53.2,"institutionHeld":0,"latestPrice":4.17,"committee":-0.969697,"eps":-67.3644,"divideRate":0,"volume":33579,"delay":0,"ttmEps":-67.3644,"open":4.22,"prevYearClose":24.7,"prevWeekClose":4.15,"prevMonthClose":4.3,"prevQuarterClose":4.635,"fiveDayClose":4.76,"twentyDayClose":5.85,"sixtyDayClose":13.016},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525318890","title":"FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2525318890","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525318890?lang=en_us&edition=fundamental","pubTime":"2025-04-08 18:46","pubTimestamp":1744109160,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics ALLO announced that the FDA has granted three fast track designations to its investigational CRISPR-based allogeneic CAR-T therapy, ALLO-329.These designations apply to three autoimmune diseases — systemic lupus erythematosus , idiopathic inflammatory myopathy  and diffuse systemic sclerosis .How Does the Fast Track Tag Benefit ALLO’s Drug Development?Fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions, meet an unmet medical need, or offer a potential advantage over existing treatments. Per the FDA, the purpose of granting this designation is to ‘get important new drugs to the patient earlier.’。In the past 60 days, estimates for CytomX Therapeutics’ 2025 EPS have improved from a loss of 31 cents to a profit of 25 cents. During the same timeframe, estimates for loss per share for 2026 have","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-grants-three-fast-track-104600523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","BK4585","BK4077","BK4007","FAST","BK4588","BK4567","SLE","IIM","ETNB","ALLO","BK4139","CTMX","IE00B5TLWC47.USD","ANIP","BK4104","IE00BFXG0V08.USD","IE00BYQQ9H92.USD"],"gpt_icon":0},{"id":"2525048864","title":"Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma","url":"https://stock-news.laohu8.com/highlight/detail?id=2525048864","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525048864?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:30","pubTimestamp":1744029000,"startTime":"0","endTime":"0","summary":"Designations Follow Recent Investigational New Drug (IND) Application Clearance for the RESOLUTION Basket Study of ALLO-329 in RheumatologyDual CD19/CD70 CAR T Specifically Designed to Enhance Therape","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056719/0/en/Allogene-Granted-Three-U-S-FDA-Fast-Track-Designations-FTD-for-ALLO-329-a-Next-Generation-Dual-Targeted-CD19-CD70-Allogeneic-CAR-T-for-the-Treatment-of-Lupus-Myositis-and-Scleroder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR","BK4139","BK4077","IE00BYQQ9H92.USD","BK4585","BK4022","FAST","SLE","BK4230","IIM","BK4588","BK4104","BK4505","IE00BFXG0V08.USD","ALLO","IE00B5TLWC47.USD","BK4567"],"gpt_icon":0},{"id":"2525732917","title":"Super League Enterprise Full Year 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2525732917","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525732917?lang=en_us&edition=fundamental","pubTime":"2025-04-05 02:59","pubTimestamp":1743793184,"startTime":"0","endTime":"0","summary":"We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqCM:SLE Earnings and Revenue History April 4th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 11%. Earnings per share  also missed analyst estimates by 20%.Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Interactive Media and Services industry in the US.Performance of the American Interactive Media and Services industry.The company's shares are down 41% from a week ago.We should say that we've discovered 5 warning signs for Super League Enterprise (3 don't sit too well with us!) that you should be aware of before investing here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/super-league-enterprise-full-2024-185944978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLE"],"gpt_icon":0},{"id":"2524419418","title":"Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524419418","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524419418?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505200,"startTime":"0","endTime":"0","summary":"LONDON, April  01, 2025  (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation progra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053144/0/en/Autolus-Therapeutics-to-Host-R-D-Investor-Event-on-Wednesday-April-23-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4181","BK4139","BK4218","LENZ","BK4077","HST","SLE","BK4588"],"gpt_icon":0},{"id":"2523926560","title":"Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2523926560","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523926560?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:20","pubTimestamp":1743427200,"startTime":"0","endTime":"0","summary":"Charles River Laboratories International, Inc.CRL and Valo Health, Inc. recently announced an advanced product candidate for the treatment of different forms of lupus and other autoimmune indications with significant unmet needs. The discovery marks the first using Logica, an artificial intelligence -powered drug development solution that translates biological insights into optimized preclinical assets.Alongside Valo Health and Flagship Pioneering’s in-house drug development unit, Pioneering Medicines, Charles River looks forward to further leveraging the power of Logica to advance this program into lead optimization.Importance of Charles River and Valo’s Combined Offering. Logica, the result of a strategic collaboration between Charles River and Valo Health, is the industry’s first computation-powered, unified target-to-candidate offering. The platform leverages the integration of Valo Health’s AI-powered Opal Computational Platform and Charles River’s leading expertise in drug discov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/charles-river-valo-healths-logica-132000618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169590202.USD","BK4548","LU0957791311.USD","LU1791710400.SGD","LU1914381329.SGD","BK4504","BK4533","LU2764262908.HKD","CRL","LU2041044095.USD","LU2125909593.SGD","IE00B2B36J28.USD","BK4535","LU1983299246.USD","LU1691799644.USD","LU1712237335.SGD","BK4077","IE00BJJMRZ35.SGD","LU0096362180.USD","LU0234572021.USD","LU2298321311.HKD","LU1670628061.USD","TMO","IE00B19Z8X17.USD","SLE","LU2125909247.SGD","SG9999004303.SGD","LU2764263203.CNY","BK4585","IE0009355771.USD","LU2092937221.SGD","BIO","LU2211815571.USD","BK4566","LU1023059063.AUD","LU1548497426.USD","ABT","LU1923621640.USD","LU1989771016.USD","SG9999002232.USD","LU1854103824.USD","BK4568","BK4530","LU2211814178.USD","LU1633808545.USD","IE00BFTCPJ56.SGD","LU1721429402.USD","LU2468319806.SGD","LU0640476718.USD","LU2764263039.SGD"],"gpt_icon":0},{"id":"2523094592","title":"GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2523094592","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523094592?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, Marc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052210/0/en/GRI-Bio-Bolsters-Intellectual-Property-Portfolio-with-Granting-of-Two-Global-Patents-for-Europe-and-Japan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLE","BK4007","GRI","BK4077"],"gpt_icon":0},{"id":"2523171969","title":"Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523171969","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523171969?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET clinical development program since ACR C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052139/0/en/Cabaletta-Bio-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1668664300.SGD","BK4516","LU0314104364.USD","LU2133065610.SGD","LU1989772923.USD","LU0158827948.USD","LU0225283273.USD","BK4534","BK4581","LU2271345857.HKD","BK4588","BK4127","LU0795875086.SGD","LU2089283258.USD","LU0912757837.SGD","LU0795875169.SGD","LU1363072403.SGD","IE00BKVL7J92.USD","BK4585","LU0267386448.USD","BK4563","LU1732800096.USD","LU0098860793.USD","LU1989772840.SGD","LU1732799900.SGD","IE00BZ1G4Q59.USD","LU2089284900.SGD","IMNM","LU0158827781.USD","BK4139","LU2357305700.SGD","CDMO","LU1720051108.HKD","LU2023251221.USD","LU2347655156.SGD","LU0106261372.USD","CABA","LU0320765646.SGD","LU0971096721.USD","LU0106831901.USD","LU2028103732.USD","LU1162221912.USD","LU2111349929.HKD","LU1074936037.SGD","BK4504","BK4077","LU0006306889.USD","LU1720051017.SGD","LU1548497426.USD","SLE"],"gpt_icon":0},{"id":"2523119796","title":"Super League Enterprise Inc (SLE) Q4 2024 Earnings Call Highlights: Strategic Shifts and Growth ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2523119796","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523119796?lang=en_us&edition=fundamental","pubTime":"2025-03-30 03:01","pubTimestamp":1743274886,"startTime":"0","endTime":"0","summary":"Revenue Diversification: Positive signs in Q1 with revenue diversification kicking in.Margins: Margins are recovering with higher-margin products added to the portfolio.Active Pursuits: Approximately $20 million in active pursuits across 77 unique programs.EBITDA Goal: Aim to be EBITDA positive in Q4.Cost Structure: Aggressively attacking cost structure to align with breakeven imperative.GuruFocus has detected 6 Warning Signs with SLE.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Super League Enterprise Inc  is optimistic about optimizing its business model to deliver meaningful shareholder value despite facing micro-cap and macroeconomic challenges.Revenue diversification is underway, with mobile games becoming a significant growth area, contributing to 16% of revenue in Q4 and expected to reach 20% in Q1.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/super-league-enterprise-inc-sle-190126765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RBLX","SLE"],"gpt_icon":0},{"id":"2522577543","title":"Super League Enterprise Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2522577543","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522577543?lang=en_us&edition=fundamental","pubTime":"2025-03-28 21:31","pubTimestamp":1743168675,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc reports results for the quarter ended December 31 - Earnings SummarySuper League Enterprise Inc SLE.OQ reported a quarterly adjusted loss of 45 cents per share for the quar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB14L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE"],"gpt_icon":0},{"id":"2522508032","title":"Super League Enterprise (SLE) Reports Q4 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522508032","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522508032?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:40","pubTimestamp":1743165602,"startTime":"0","endTime":"0","summary":"Super League Enterprise  came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $3.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -28.57%. A quarter ago, it was expected that this company would post a loss of $0.28 per share when it actually produced a loss of $0.54, delivering a surprise of -92.86%.Super League Enterprise , which belongs to the Zacks Gaming industry, posted revenues of $3.43 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 31.48%. This compares to year-ago revenues of $9.51 million. The company has not been able to beat consensus revenue estimates over the last four quarters.Super League Enterprise shares have lost about 35.9% since the beginning of the year versus the S&P 500's decline of -3.2%.While Super League Enterprise has underperformed the market so far this year, t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/super-league-enterprise-sle-reports-124002934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLE","LVS"],"gpt_icon":0},{"id":"2522784175","title":"BRIEF-Super League Enterprise President Matt Edelman Promoted To Role Of Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522784175","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522784175?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:49","pubTimestamp":1743162555,"startTime":"0","endTime":"0","summary":"BRIEF-Super League Enterprise President Matt Edelman Promoted To Role Of Chief Executive OfficerMarch 28 (Reuters) - Super League Enterprise Inc SLE.O:SUPER LEAGUE ENTERPRISE INC - PRESIDENT MATT EDEL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0XJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2522520479","title":"Super League Enterprise Q4 2024 Adj EPS $(0.29) Misses $(0.26) Estimate, Sales $3.43M Miss $5.50M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522520479","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522520479?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:35","pubTimestamp":1743161727,"startTime":"0","endTime":"0","summary":"Super League Enterprise (NASDAQ:SLE) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.26) by 11.54 percent. This is a 61.33 percent increase over losses of $(0.75) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44533697/super-league-enterprise-q4-2024-adj-eps-0-29-misses-0-26-estimate-sales-3-43m-miss-5-50m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE"],"gpt_icon":0},{"id":"2522520528","title":"Press Release: Super League Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Update on Strategic Discussions to Accelerate Path to Profitability and Diversify Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2522520528","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522520528?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:30","pubTimestamp":1743161400,"startTime":"0","endTime":"0","summary":"Super League Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Update on Strategic Discussions to Accelerate Path to Profitability and Diversify Revenues. Ann Hand to Support Strategic Alternative Initiatives as Executive Chair; President Matt Edelman Promoted to the Role of Chief Executive Officer. Renowned Marketing and Advertising Executive Bant Breen Appointed to Board of Directors. SANTA MONICA, Calif., March 28, 2025  -- Super League , a leader in redefining the gaming industry as a media channel, today released fourth quarter and full year 2024 financial results.In an effort to bolster our Board, we are thrilled to appoint Bant Breen as a Director. Bant is a noted marketing and media executive, entrepreneur and academic. Specifically, Bant has spent a vast amount of his career in holding company and operating leadership roles with some of the largest global ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","AAQC"],"gpt_icon":0},{"id":"2522184495","title":"Dow Dips 150 Points Following Trump's Auto Tariffs, Verint Systems Slides On Q4 Miss: Greed Index Remains In 'Fear' Zone","url":"https://stock-news.laohu8.com/highlight/detail?id=2522184495","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522184495?lang=en_us&edition=fundamental","pubTime":"2025-03-28 14:08","pubTimestamp":1743142102,"startTime":"0","endTime":"0","summary":"U.S. markets closed lower on Thursday due to tariff news, with little change in the CNN Fear &amp; Greed index. S&amp;P 500 and Nasdaq also fell.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44529927/dow-dips-150-points-following-trumps-auto-tariffs-verint-systems-slides-on-q4-miss-greed-index-remains-in-fear-zone","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCOM","KPLT","VRNT","TQQQ","MBGAF","BK4077","PSQ","QID","NVIW.SI","LU1559883803.SGD","NQmain","SNX","BK4023","USJW.SI","BK4122","BK4099","BK4140","BK4166","TSYW.SI","POAHF","QLD","USAW.SI","MNQmain",".IXIC","SLE","LU0566484027.USD","SQQQ"],"gpt_icon":1},{"id":"2522330921","title":"Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522330921","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522330921?lang=en_us&edition=fundamental","pubTime":"2025-03-27 04:01","pubTimestamp":1743019260,"startTime":"0","endTime":"0","summary":"Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases. Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025. Restructuring and workforce reduction of 34% , including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestones. Cash balance of $380.5 million on December 31, 2024, including cash, cash equivalents and investments, expected to fund operations into 2029. NKX019 is an allogeneic, off-the-shelf, chimeric antigen receptor  NK-cell therapy candidate engineered to deplete CD19-positive cells in B-cell mediated autoimmune disease. The approach leverages the potential advantages of NK cell therapy, including deep and rapid B-cell killing, a lower risk of cytokine release syndrome and neurotoxicity, the opportunity for pot","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nkarta-reports-fourth-quarter-full-200100807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZL793.SGD","BK4077","MG","BK4230","IE00B19Z4B17.USD","BK4139","IE00B66KJ199.SGD","BK4022","SLE","CAR","BK4505","IE0031619046.USD","BK4123","NKTX"],"gpt_icon":0},{"id":"2522887962","title":"Press Release: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522887962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522887962?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:05","pubTimestamp":1742933100,"startTime":"0","endTime":"0","summary":"Received Clearance from the U.S. Food and Drug Administration  for Clinical Trials of Budoprutug in Primary Membranous Nephropathy , Immune Thrombocytopenia , and Systemic Lupus Erythematosus . Completed Studies to Support Process Optimization through Cell Line Switch for Budoprutug and Filed Additional Patent Applications to Further Strengthen Intellectual Property Position. Expanded Pipeline to Include CLYM116, an Anti-APRIL  Monoclonal Antibody for Treatment of IgA Nephropathy . Appointed Perrin Wilson, Ph.D. as Chief Business Officer. Ended 2024 in a Strong Financial Position, with Cash Runway Expected Through 2027. received clearance from the FDA to initiate a Phase 2 clinical trial of. budoprutug in patients with pMN. This open-label, dose-ranging","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ITP","BK4199","CLYM","BK4077","SLE"],"gpt_icon":0},{"id":"2522707632","title":"Press Release: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707632","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707632?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:05","pubTimestamp":1742846700,"startTime":"0","endTime":"0","summary":"Initial data for AlloNK from autoimmune program expected H1 2025. Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025. Strengthened key leadership with cell therapy and autoimmune expertise across organization. Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026. SAN DIEGO, March 24, 2025  -- Artiva Biotherapeutics, Inc.  , a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the full year ended December 31, 2024, and highlighted recent progress.Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","SLE","BK4139","BK4022","ARTV","BK4232","RA","BK4077"],"gpt_icon":0},{"id":"2521205319","title":"Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2521205319","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521205319?lang=en_us&edition=fundamental","pubTime":"2025-03-23 20:43","pubTimestamp":1742733837,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where Adicet Bio, Inc.  stands against other penny stocks with the biggest upside potential.Further insights came from Chris Retzler, portfolio manager for Needham’s Small Cap Growth Fund, who shared his outlook for small-caps on CNBC’sSquawk Boxon January 17, 2025. He noted that small-cap companies are looking for policy certainty, and once the new administration’s direction becomes clearer, we could see growth accelerate. Globally, the EV sector is thriving, even as it faces some hurdles in the United States.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-acet-among-penny-124357821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","SQQQ","QID","USJW.SI","PSQ",".IXIC","NVIW.SI","TSYW.SI","SLE","USAW.SI","ACET","TQQQ","BK4077","MNQmain","QLD","BK4139"],"gpt_icon":1},{"id":"2521402902","title":"Super League Enterprise Inc  expected to post a loss of 26 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521402902","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521402902?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:13","pubTimestamp":1742555586,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc  expected to post a loss of26cents a share - Earnings Preview Super League Enterprise Inc SLE.OQ SLE.O is expected to show a fall in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q40RQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE"],"gpt_icon":0},{"id":"2520437679","title":"Press Release: Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520437679","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520437679?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:00","pubTimestamp":1742468400,"startTime":"0","endTime":"0","summary":"on track with 33 authorized treatment centers as of March 19, 2025,-- Obe-cel MHRA and EMA marketing authorizations expected in H2 2025. -- Initial six patients dosed in Phase 1 dose confirmation trial in Systemic. -- Company to provide clinical development program updates, including plans. for expansion in autoimmune diseases, at R&D investor event to be held on. call participants should pre-register using the link at the bottom of. \"As we begin 2025, we have two key objectives: execute on the commercial launch of AUCATZYL in adult ALL both in the U.S. and entering new markets; and establish the next wave of investments to expand the obe-cel opportunity, advance our clinical pipeline and drive future growth. We look forward to discussing our plans to continue to expand our clinical pipeline and strategy at our R&D event in April.\".  for the treatment of adult patients with relapsed or","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0985320562.USD","LU1699723380.USD","BK4109","ASH","LENZ","BK4585","SOHO","NICE","BK4218","EBMT","BK4211","LU1571399168.USD","BK4232","BK4077","R","BK4023","BK4588","BK4022","AUTL","ALL","BK4543","LU2355687059.USD","SLE","IE00BFMHRM44.USD","BK4181","BK4139","LU2463526074.USD","BK4533","BK4107"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":96,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-06-23","symbol":"SLE","defaultRemindTime":1750685400000,"type":"split","dateTimestamp":1750651200000,"forFactor":40,"toFactor":1,"ratio":40},{"market":"US","date":"2025-05-15","symbol":"SLE","fiscalQuarterEnding":"2025/03","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-03-28","symbol":"SLE","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2024-11-14","symbol":"SLE","fiscalQuarterEnding":"2024/09","expectedEps":-0.28,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.54},{"market":"US","date":"2024-08-14","symbol":"SLE","fiscalQuarterEnding":"2024/06","expectedEps":-0.62,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1694059200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2025-08-05","current":-0.235844,"percent":0.668889,"low":-0.555206,"twenty":-0.336743,"median":-0.274166,"eighty":-0.21136,"high":-0.044016,"avg":-0.271708,"sd":0.100725,"marketCap":3680347},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387},{"date":"2025-06-20","current":-0.204904,"twenty":-0.346791,"median":-0.280097,"eighty":-0.210029,"marketCap":3197521},{"date":"2025-06-27","current":-0.222294,"twenty":-0.344958,"median":-0.279367,"eighty":-0.209283,"marketCap":3468896},{"date":"2025-07-03","current":-0.240225,"twenty":-0.342139,"median":-0.277573,"eighty":-0.209588,"marketCap":3748716},{"date":"2025-07-11","current":-0.314762,"twenty":-0.339781,"median":-0.277296,"eighty":-0.209879,"marketCap":4911855},{"date":"2025-07-18","current":-0.242124,"twenty":-0.33814,"median":-0.276346,"eighty":-0.210021,"marketCap":3778350},{"date":"2025-07-25","current":-0.228831,"twenty":-0.337327,"median":-0.276269,"eighty":-0.210038,"marketCap":3570911},{"date":"2025-08-01","current":-0.243781,"twenty":-0.33696,"median":-0.274358,"eighty":-0.210831,"marketCap":3804205},{"date":"2025-08-05","current":-0.235844,"twenty":-0.336743,"median":-0.274166,"eighty":-0.21136,"marketCap":3680347}],"updateTime":1754473820581}}}